Arix Bioscience and 5AM Ventures led a $135m Series B round in Ensoma.

Arix Bioscience and 5AM Ventures led a $135m Series B round in Ensoma, a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications, with participation from F-Prime Capital, Cormorant Asset Management, Viking Global Investors, Takeda Ventures, SymBiosis, Alexandria Venture Investments, Fred Hutchinson Cancer Center, Bill & Melinda Gates Foundation, Qatar Investment Authority (QIA), Catalio Capital Management, Solasta Ventures, Mirae Asset, Bioluminescence Ventures, and Delos Capital. “With a single outpatient treatment, Ensoma’s Engenious platform empowers patients’ own cells to cure disease. This opens new diseases and geographies to the power of in vivo genomic medicines, dramatically simplifies the logistics of treatment and will eliminate much of the burden of treatment on the healthcare system and the patient. We are excited to partner with the Ensoma team to be a part of this next chapter,” Mark Chin, Arix Bioscience Managing Director.